Skip to main content
Marc Sabatine, MD, Cardiology, Boston, MA

MarcSabatineMD

Cardiology • Boston, MA

Adult Congenital Heart Disease

Associate Professor of Medicine, Brigham and Women's Hospital.

Join to view full profile

Dr. Sabatine is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Sabatine's full profile

Already have an account?

  • Office

    75 Francis St
    Brigham And Womens Hospital Cardiovascular Division
    Boston, MA 02115
    Phone+1 617-278-0145

Education & Training

  • Massachusetts General Hospital
    Massachusetts General HospitalFellowship, Cardiovascular Disease, 1995 - 2002
  • Massachusetts General Hospital
    Massachusetts General HospitalResidency, Internal Medicine, 1995 - 1998
  • Harvard Medical School
    Harvard Medical SchoolClass of 1995

Certifications & Licensure

  • MA State Medical License
    MA State Medical License 2000 - 2025
  • American Board of Internal Medicine Cardiovascular Disease

Awards, Honors, & Recognition

  • Elected Member The American Society for Clinical Investigation, 2012
  • Fellow (FACC) American College of Cardiology

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Time to Clinical Benefit of Dapagliflozin and Significance of Prior Heart Failure Hospitalization in Patients with Heart Failure with Reduced Ejection Fraction  
    Mikhail N Kosiborod, Marc S Sabatine, JAMA Cardiology
  • Association of Baseline Low-Density Lipoprotein Cholesterol and Percentage Low-Density Lipoprotein Cholesterol Reduction with Statins, Ezetimibe, and PCSK9 Inhibition  
    Robert P Giugliano, Marc S Sabatine, JAMA Cardiology
  • PCSK9 Inhibition—A Tale of 2 Potential Treatment Opportunities—Reply  
    Brian A Bergmark, Marc S Sabatine, JAMA Cardiology
  • Join now to see all

Lectures

  • PCSK9 Inhibitors: What We Know What We Don't Know and Where are We Going? 
    2019 ACC Scientific Session & Expo, New Orleans - 3/17/2019

Authored Content

  • Efficacy and Safety of PCSK9 Inhibition with Evolocumab in Reducing Cardiovascular Events in Patients with Metabolic Syndrome Receiving Statin TherapyAugust 2020
  • Efficacy and Safety of PCSK9 Inhibition with Evolocumab in Reducing Cardiovascular Events in Patients with Metabolic Syndrome Receiving Statin TherapyAugust 2020
  • Clinical Application of High-Sensitivity Troponin Testing in the Atherosclerotic Cardiovascular Disease Framework of the Current Cholesterol GuidelinesAugust 2020
  • Efficacy of Evolocumab on Cardiovascular Outcomes in Patients with Recent Myocardial InfarctionMay 2020
  • Efficacy of Evolocumab on Cardiovascular Outcomes in Patients with Recent Myocardial InfarctionMay 2020
  • Ticagrelor for Secondary Prevention of Atherothrombotic Events in Patients with Multivessel Coronary DiseaseJanuary 2018
  • Reply Cost-Effectiveness of Long-Term Ticagrelor in Patients with Prior Myocardial Infarction: Analysis by SubgroupsJanuary 2018
  • Join now to see all

Press Mentions

  • First Patient Enrolled in Phase 3 Trial Evaluating Abelacimab in High-Risk Patients with Atrial Fibrillation Deemed Unsuitable for Current Anticoagulants
    First Patient Enrolled in Phase 3 Trial Evaluating Abelacimab in High-Risk Patients with Atrial Fibrillation Deemed Unsuitable for Current AnticoagulantsJanuary 3rd, 2023
  • Statins Boost Glycemia Slightly, but CVD Benefits Prevail
    Statins Boost Glycemia Slightly, but CVD Benefits PrevailNovember 14th, 2022
  • Amgen Presents New Repatha® (Evolocumab) Data at Aha 2022
    Amgen Presents New Repatha® (Evolocumab) Data at Aha 2022November 7th, 2022
  • Join now to see all

Committees

  • member, 2014 AHA/ACC NSTE-ACS Guideline

Professional Memberships

Dr. Marc Sabatine, Dr. Marc Sabatine, MD, Dr. M Sabatine